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Objectives: The purpose of this study was to assess the effect of community-wide performance measurement and feedback
on key processes and outcomes of carotid endarterectomy (CEA).
Methods: Complete medical record (hospital chart) review for indications, care processes, and outcomes was performed on
a random sample of Medicare patients undergoing CEA in 10 states (Arkansas, Georgia, Illinois, Indiana, Iowa,
Kentucky, Michigan, Nebraska, Ohio, Oklahoma) during baseline (Jun 1, 1995 to May 31, 1996) and remeasurement
(Jun 1, 1998 to May 31, 1999) periods. In addition to review of the index hospital stay, hospital admissions within 30
days of the procedure were reviewed and the Medicare enrollment database queried to identify out-of-hospital deaths, to
determine 30-day outcome results. The baseline data by state were provided to the Medicare Quality Improvement
Organizations (QIOs) in the respective states, and quality improvement initiatives were encouraged.
Results: We reviewed 9945 primary CEA alone procedures, 236 CEA and coronary artery bypass grafting (CABG) procedures,
and 380 repeat CEA operations during the baseline period (B), and 9745 primary CEA alone procedures, 233 CEA and CABG
procedures, and 401 repeat CEA operations during the remeasurement period (R). There was a significant decrease in the
combined event rate (30-day stroke or mortality) for CEA alone procedures between baseline and remeasurement (B, 5.6%; R,
5.0%). A decrease occurred in each of the indication strata; transient ischemic attack or stroke (B, 7.7%; R, 6.9%), nonspecific
symptoms (B, 5.9%; R, 5.4%), and no symptoms (B, 4.1%; R, 3.8%). The combined event rate also decreased for CEA and
CABG (B, 17.4%; R, 13.3%) and repeat CEA operations (B, 6.8%; R, 5.7%). The remeasurement period state-to-state variation
in combined event rate for CEA alone ranged from 2.7% (Georgia) to 5.9% (Indiana) for all indications combined, from 4.4%
(Georgia) to 10.9% (Michigan) in patients with recent transient ischemia or stroke, from 1.4% (Georgia) to 6.0% (Oklahoma)
in patients with no symptoms, and from 3.7% (Georgia) to 7.9% (Indiana) in patients with nonspecific symptoms. There were
significant increases in preoperative antiplatelet administration (62%-67%; P < .0001) and patching (29%-45%; P .05) from
baseline to remeasurement in the CEA alone subset. Preoperative antiplatelet administration and patching were associated with
improved outcomes in the combined baseline and remeasurement data.
Conclusions: Community-wide quality improvement initiatives with performance measurement and confidential reporting of
provider level data can lead to improvement in important care processes and outcomes. There is considerable variation between
states in outcome and process, and thus continued room for improvement. Quality improvement projects that include
standardized confidential outcome reporting should be encouraged. Preoperative antiplatelet therapy administration and
patching rates should be considered as evidence-based performance measures. (J Vasc Surg 2004;39:372-80.)
The efficacy of carotid endarterectomy (CEA) in stroke
prevention for patients with symptomatic and asymptom-
atic carotid stenosis has been well-established in random-
ized trials.1-5 Community-wide outcome surveys have of-
ten documented outcomes inferior to the results achieved
in the randomized trials.6-9 Some have advocated public
reporting of outcomes as a necessary means of improving
surgical outcomes in the community.10 Others have used
confidential feedback of hospital or physician level outcome
data in multi-institutional quality improvement ef-
forts.11-13 An alternative or complementary performance
measurement strategy to outcome reporting is the use of
process measures. Process measures use care processes (eg,
administration of preoperative antiplatelet agents before
CEA) that have been linked to improved outcomes as
indicators of quality. Process quality measures have the
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advantage of often requiring less risk adjustment than out-
come measures, and are more readily actionable by health
care professionals.
The Centers for Medicare & Medicaid Services (CMS)
began the Health Care Quality Improvement Program
(HCQIP) in 1992.14 The HCQIP directed Medicare
Quality Improvement Organizations (QIOs) to initiate
quality improvement projects within their states. A number
of these initiatives have been expanded to the national
level.15 A CEA pilot project was carried out as part of the
HCQIP in 10 states. The baseline data from the 10-state
CEA project has been reported.9 The current report details
the remeasurement data from this 10-state project after
quality improvement activities were encouraged by the
local QIOs.
METHODS
A complete medical record (hospital chart) review for
indications, care processes, and outcomes was performed
on a random sample of Medicare patients undergoing CEA
(International Classification of Diseases, 9th revision, Clin-
ical Modification [ICD-9-CM] procedure code 38.12,
endarterectomy of vessels of head and neck) in 10 states
(Arkansas, Georgia, Illinois, Indiana, Iowa, Kentucky,
Michigan, Nebraska, Ohio, Oklahoma) during baseline
and remeasurement 12-month periods separated by a
3-year interval. The sampling strategy was designed to
obtain an adequate number of cases from each of the states,
based on a power calculation using an estimated frequency
of combined events (stroke or mortality) of 6% with a 95%
confidence interval and SEM  1.5%. A 50% oversampling
of the calculated individual state samples, except Iowa and
Nebraska, which had 100% of cases selected because of
ongoing CEA quality improvement projects, resulted in a
sampling fraction that varied from 0.2 to 1.0.
In addition to review of the index hospital stay, hospital
admissions within 30 days of the procedure were identified.
The complete medical record from any of these hospital
readmissions with an admitting or discharge diagnosis code
suggesting a cerebrovascular accident (ICD-9 codes 430-
438, cerebrovascular disease; 784.3, aphasia; 784.5, dys-
phasia; 342, hemiplegia; 344, paralysis) were reviewed. In
addition to the review of hospital readmissions the Medi-
care enrollment database was queried to identify out-of-
hospital deaths, to determine complete 30-day outcome
results. The baseline sample (10,561 procedures) included
discharges between Jun 1, 1995, and May 31, 1996. The
remeasurement sample (10,379 procedures) included dis-
charges between Jun 1, 1998 and May 31, 1999.
Requests for copies of the entire medical record for the
primary admission and any readmissions were sent to the
hospitals. Compliance with these requests is mandated by
federal statute as part of participation in the Medicare
program. The costs associated with copying and mailing
medical records were reimbursed to the institution. A data
collection tool was created for medical record abstraction
by trained abstractors. Each medical record was compre-
hensively reviewed to determine patient demographic data,
indication for the procedure, perioperative care processes,
and postoperative outcomes. The records were reviewed by
trained abstractors at a CMS Clinical Data Abstraction
Center (DynKePRO, York, Pa). Data were abstracted from
medical records directly into a computerized data entry
system with an online edit check and data definitions to
improve accuracy of data collection. Data definitions for
procedure classification, procedural indication, and out-
come have been described.9
For the original project and publication an extensive
effort was made to validate the Clinical Data Abstraction
Center abstraction process with respect to identification
and classification (major vs minor stroke) of adverse out-
comes. The medical records of all patients identified as
having postoperative stroke after the initial chart abstrac-
tion were independently reviewed again by two clinicians
with expertise in stroke. This process resulted in a slight
decrease in the overall observed combined event rate, 5.6%
unvalidated versus 5.2% after the independent clinician
validation. The validation process was not performed for
the remeasurement sample, and therefore for the purpose
of this report the unvalidated data were used from the
baseline sample to allow appropriate comparison with the
remeasurement data.
The baseline data by state were provided to the Medi-
care QIOs in the respective states, and quality improvement
initiatives were encouraged. The specific quality improve-
ment efforts in the individual states were voluntary and not
standardized. Four states (Georgia, Iowa, Ohio, Okla-
homa) had projects focused on CEA outcomes that pre-
ceded the 10-state initiative.6,13,16,17 These projects had all
used review of hospital records of CEA admissions to
determine outcome rates and provide institution level feed-
back. The Georgia, Iowa, and Ohio projects were state-
wide, while the Oklahoma project focused on eight hospi-
tals. The Iowa project involved support of ongoing
voluntary data collection and periodic feedback of process
and outcome data. This approach was expanded to Illinois,
Nebraska, and Oklahoma as part of the 10-state initiative.
The QIOs in Indiana and Kentucky provided feedback of
the data to institutions in their states and encouraged
quality improvement efforts. No specific quality improve-
ment projects were carried out in Arkansas or Michigan. All
provider level (hospital or surgeon) data were confidential.
Data analysis. We examined simple descriptive statis-
tics for the processes and outcomes of CEA care. We tested
for the significance of the difference between the baseline
and remeasurement samples with the Mantel-Haenszel 2
statistic as computed in Epi Info, version 6.
To examine the relative effect of different processes of
care on CEA outcomes in the CEA alone subgroup, we first
evaluated each process as an independent variable. To
account for the effect of indication, each process was exam-
ined with a multivariate logistic regression model, with the
combined event rate as the dependent variable. The inde-
pendent variables in each model were dichotomous vari-
ables representing the process and each indication. PROC
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LOGISTIC (version 8.0; SAS Institute, Cary, NC) was
used to compute the Wald 2 statistics.
RESULTS
The comparison between the baseline and remeasure-
ment samples is displayed in Fig 1. A detailed comparison of
the baseline and remeasurement samples including demo-
graphic data, processes, and outcomes is available in the
Appendix (Tables I and II, online only). The combined
event rate (30-day stroke or mortality) in the CEA alone
subset decreased from 5.6% in the baseline period to 5.0%
in the remeasurement sample (P  .05). In the baseline
period 79% of strokes were ipsilateral to the CEA, and 60%
occurred on the day of or the day after operation. In the
remeasurement period the ipsilateral stroke rate was 76%,
and 63% occurred by postoperative day 1. Although there
were some changes in the indication distribution between
baseline and remeasurement, the combined event rate de-
creased in each of the indication strata (transient ischemic
attack or stroke, nonspecific symptoms, and no symptoms),
indicating that the overall decrease in combined event rate
was not a result of a change in indication distribution. The
CEA and coronary artery bypass grafting combined event
rate was 17.4% in the baseline sample and 13.3% in the
remeasurement period. The repeat operation combined
event rate was 6.8% in the baseline period and 5.7% in the
remeasurement period.
The state-by-state comparison from baseline to remea-
surement is displayed in Figs 2 and 3 and Table III. It can
be seen that the state that was an outlier with respect to
significantly higher combined event rates in the baseline
CEA alone sample (Oklahoma) was no longer significantly
different from the others in the remeasurement sample.
The only state outlier for CEA alone (all indications com-
bined) in the remeasurement sample was Georgia, which at
2.7% had a significantly lower combined event rate com-
pared with the other states. Two states, Georgia and Okla-
homa, showed a decrease in the combined event rate from
baseline to remeasurement that was statistically significant
(P  .05). Fig 3 shows that patching went up significantly
in every state, but variation still exists.
The length of stay decreased from a median of 4.0 days
in the baseline period to 3.0 days in the remeasurement
period, although the postoperative median length of stay
Fig 1. Combined event rate (30-day stroke or mortality) and mortality rate for 10-state aggregate for each procedure
category: CEA alone, BN  9945, RN  9745; CEA and CABG, BN  236, RN  233; and CEA redo, BN  380,
RN  401. CEA alone indication subsets: Stroke/TIA, BN  2341, RN  1852; nonspecific, BN  3713, RN 
3800; and asymptomatic, BN 3891, RN 4093. CEA, Carotid endarterectomy; TIA, transient ischemic attack; B,
baseline period, Jun 1, 1995, to May 31, 1996; R, remeasurement period, Jun 1, 1998, to May 31, 1999; BN, baseline
number of procedures; RN, remeasurement number of procedures. †Significantly different from baseline to remea-
surement, P  .05.
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was unchanged, at 2.0 days. The proportion of patients
with identified preoperative arteriograms was 71% at base-
line and 64% at remeasurement. The rate of patching
increased from 29% at baseline to 45% at remeasurement (P
 .05), and preoperative antiplatelet therapy increased
from 62% in the baseline period to 67% in the remeasure-
ment period (P  .0001). With the combined CEA alone
dataset (19,690 procedures from the baseline and remea-
surement periods), preoperative antiplatelet therapy (odds
ratio [OR} 0.73; P .0001) and patching (OR, 0.88; P
.05) were associated with lower combined event rates in a
model accounting for procedural indication (Table IV).
DISCUSSION
Quality of care and patient safety have been the focus of
a great deal of interest in both the medical community and
the public at large. The public interest has been sparked by
media coverage of reports from the Institute of Medi-
cine.18,19 Various strategies have been proposed to stimu-
late quality improvement. One approach that is exemplified
by the New York State Department of Health cardiac
surgery project has been public reporting of outcome da-
ta.10 The difficulty in collecting important clinical data, the
lack of robust risk adjustment models, and the limited
ability to properly define outcomes other than mortality
have restricted the use of this approach for other surgical
procedures. In addition, there is scant evidence that the
public uses the information, and concerns have been raised
about the potential adverse consequences of public report-
ing of surgeon-specific data, such as decreasing access to
care for patients at high risk. For many procedures valid risk
adjustment models are not available, and typical surgical
volumes make statistically valid comparisons between sur-
geons or hospitals impossible.20
Because of the difficulties in standardized, risk-adjusted
outcome reporting that can provide statistically valid sur-
geon or even hospital-level comparison for many surgical
procedures, procedural volume has been proposed as an
alternative “quality measure” for public reporting. This has
been a major component of the Leapfrog initiative, which is
Fig 2. Combined event rate (30-day stroke or mortality) and mortality rate for CEA alone procedures (all indications)
by state. Arkansas, BN 770, RN 828); Georgia, BN 958, RN 928); Illinois, BN 1064, RN 1035; Indiana,
BN 1026, RN 1005; Iowa, BN 1265, RN 1260; Kentucky, BN 892, RN 846; Michigan, BN 1141,
RN  1118; Nebraska, BN  865, RN  820; Ohio, BN  1143, RN  1125; Oklahoma, BN  821, RN  780.
CEA, Carotid endarterectomy; B, baseline period, Jun 1, 1995, to May 31, 1996; R, remeasurement period, Jun 1,
1998, to May 31, 1999; BN, baseline number of procedures; RN, remeasurement number of procedures. *Significantly
different from the mean, P  .05. †Significantly different from baseline to remeasurement, P  .05.
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an employer-funded effort to stimulate improved quality of
care.21 Reports on the relationship between volume and
outcome for CEA show discrepant results.22-27 Some high-
volume surgeons have poor outcomes, and some low-
volume surgeons have excellent outcomes. Even in the
reports that have found a relationship between volume and
outcome, the outcome differences have been small, and the
thresholds for the volume effect at the hospital or physician
level varied widely. Many of the reports suggesting a rela-
tionship between high volume and better outcomes have
used administrative data that do not allow stratification by
indications. The most important predictor of surgical out-
come for CEA is the indication for the procedure. If indi-
cation is not taken into account, the volume-outcome
relationship may be explained by the higher percentage of
patients without symptoms operated on by high-volume
surgeons.
An important concept in performance measurement is
the unintended consequences or perverse incentives that
some measures may create. Use of volume standards alone
as a surrogate for true quality measurement may lead to
inappropriate use. The variation in CEA use between states
is substantial. We have demonstrated previously that the
variation occurs in patients who do not have transient
ischemia or stroke as the indication for the procedure
(asymptomatic or nonspecific indications).9 The benefit of
CEA in patients without symptoms depends on very low
procedural morbidity and mortality rates. If the message to
surgeons is that quality is going to be measured by how
many procedures are performed, it seems obvious how
some will respond. If the use of volume standards alone for
CEA leads to more procedures in patients without symp-
toms without monitoring of and improvement in adverse
event rates, the overall result may be more adverse out-
comes and cost to the system, rather than improvement in
patient care.
An alternative approach to surgical quality improve-
ment is the model used by the Northern New England
Cardiovascular Disease Study Group (NNECDSG),11 the
Department of Veteran Affairs National Surgical Quality
Improvement Project (DVANSQIP),12 and this 10-state
pilot project for CMS. These efforts used the confidential
feedback of risk-adjusted outcomes to providers along with
peer comparison. There are several advantages to confiden-
Fig 3. Use of patch angioplasty for CEA alone procedures (all indications) by state. CEA alone, BN  9945, RN 
9745. CEA, Carotid endarterectomy; B, baseline period, Jun 1, 1995, to May 31, 1996; R, remeasurement period, Jun
1, 1998, to May 31, 1999; BN, baseline number of procedures; RN, remeasurement number of procedures.
†Significantly different from baseline to remeasurement, P  .05.
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tial feedback of outcome data. Since the specter of public
disclosure is avoided, the likelihood of “gaming” the sys-
tem by overestimating risk adjustment variables and avoid-
ance of patients at high risk is decreased. The concern about
statistical significance of individual comparisons is also less-
ened. By avoiding the public labeling of certain surgeons as
“bad apples,” a focus on quality improvement and moving
the group toward the benchmark level is easier to achieve.
There is no pressure to increase volume to meet some target
level.
Another important component of this pilot project and
the NNECDSG is the use of process measures, for example,
preoperative administration of antiplatelet agents for CEA
in this project. Process measures that are linked to better
outcomes have advantages over outcome measures. Most
process measures require less risk adjustment than outcome
measures; thus statistically valid comparisons are more
likely. Process measures are also more readily actionable by
the physician; that is, they provide a specific means of
quality improvement as opposed to outcome reporting
alone. Most process measures are not susceptible to the
unintended adverse consequences of outcome reporting
and volume reporting discussed above. The major limita-
tion of the use of process measures for surgical procedures
is the limited number of processes with strong evidence
links to better outcomes. Our data suggest that only pre-
operative administration of antiplatelet agents and patching
are suitable process measures for CEA. Nonetheless, our
data also suggest that there is room for improvement in
both of these areas.
The overall improvement in combined event rate
(death or any stroke) may seem modest (5.6%-5.0%). How-
ever, if one extrapolates from the approximately 92,000
CEA alone procedures performed in the Medicare popula-
Table III. Outcomes (CEA alone): Remeasurement
State
Ark Ga Ill Ind Iowa Ky Mich Neb Ohio Okla All
Stroke/mortality
Stroke or mortality (%) 5.2 2.7 4.9 5.9 5.2 4.8 5.6 4.4 5.2 5.5 5.0
Mortality (%) 1.3 0.6 2.0 1.9 1.4 1.1 1.1 1.3 1.1 1.5 1.3
With major stroke 0.6 0.4 0.9 0.6 0.3 0.4 0.4 0.7 0.4 0.5 0.5
(No major stroke) 0.7 0.2 1.2 1.3 1.1 0.7 0.6 0.6 0.6 1.0 0.8
Nonfatal stroke (%) 3.9 2.0 2.9 4.0 3.8 3.8 4.6 3.0 4.2 4.0 3.6
Major stroke 2.3 1.4 1.8 2.1 1.6 2.1 2.7 1.6 2.1 2.6 2.0
Minor stroke 1.6 0.6 1.1 1.9 2.2 1.7 1.9 1.5 2.0 1.4 1.6
Stroke or mortality by indication (%)
Ipsilateral stroke/TIA 5.3 4.4 7.9 6.3 7.1 4.8 10.9* 7.5 5.4 8.6 6.9
Nonspecific 5.8 3.7 5.2 7.9* 5.3 5.5 6.6 5.0 4.6 4.3 5.4
Asymptomatic 4.5 1.4* 3.2 3.9 4.3 4.3 2.5 2.3 5.8* 6.0* 3.8
Other outcomes
Hemorrhage requiring return to OR 1.3 2.4 2.0 1.6 2.0 1.4 1.6 1.8 1.6 2.6 1.8
Cranial nerve injury 1.6 1.2 2.1 2.7† 2.2 1.2 2.1 1.5 2.4 1.2 1.9
TIA, Transient ischemic attack; OR, operating room.
*Indicates statistically significant difference from aggregate; P  .05, while controlling for indication.
†Indicates statistically significant difference from aggregate, P  .05.
Table IV. Process/outcome relationship (CEA alone, corrected for indication): Combined baseline and remeasurement
datasets
Stroke or mortality as predicted by P OR 95% CI
Preoperative angiography .62 1.04 0.90-1.19
Preoperative aspirin/ticlid* .0001 0.73 0.65-0.83
Local/regional anesthesia .28 0.89 0.72-1.10
Use of heparin .23 0.73 0.44-1.22
Reversal of heparin therapy .74 0.98 0.86-1.11
Use of patch* .05 0.88 0.77-1.00
Use of vein patch .33 1.12 0.89-1.42
Use of prosthetic patch* .01 0.83 0.72-0.96
Use of electroencephalagraphy .56 1.05 0.89-1.24
Monitoring of backpressure .37 0.88 0.67-1.16
Shunt, no monitoring .58 0.97 0.85-1.09
No monitoring, no shunt .29 1.09 0.93-1.27
Post-reconstruction assessment .73 1.02 0.90-1.17
OR, Odds ratio; CI, confidence interval.
*Statistically significant predictor of stroke or mortality, P  .05, while controlling for indication.
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tion nationally, this level of drop in adverse outcomes
translates into more than 550 fewer deaths or strokes that
year. If the national rate had been at the benchmark level
achieved in the state of Georgia, more than 2100 additional
strokes or deaths would have been prevented. The results in
Georgia may be the most important outcome finding from
this study. The overall 4.2% combined event rate and the
1.4% combined event rate in patients without symptoms
demonstrates that benchmark outcomes can be achieved in
the community setting across an entire state. The 1.4%
event rate in patients without symptoms is remarkably
similar to the 1.5% event rate that was observed by the
surgeons in the Asymtomatic Carotid Atherosclerosis
Study (ACAS), despite the fact that the rigid selection
criteria for patients and surgeons in the trial were not
applicable.28
The relatively high overall risk for death or stroke after
CEA in asymptomatic patients (3.8%), observed even in the
remeasurement period, is concerning. This level of adverse
outcomes approaches the rate at which benefit is question-
able. The ACAS trial results and the rate in Georgia dem-
onstrate that a combined event rate of 1.5% is achievable in
patients without symptoms. The observed postoperative
combined event rate, however, should not be seen as a
justification for alternative procedures to CEA. In the
ACAS trial the stroke risk from angiography alone was
similar to the surgical event rate. It is unlikely that adding
angioplasty and stenting could be shown to have a lower
event rate than the Georgia benchmark surgical results. It
also seems likely that the increased rate of adverse events
observed in this community-wide study, compared with
research trials or selected institution results, is equally if not
more likely to be seen for carotid angioplasty and stenting.
The observations in this study should suggest the need for
similar community outcome monitoring and reporting for
carotid angioplasty and stenting, using the same indication
and outcome definitions, rather than being a justification
for the newer procedure.
Although we demonstrated significant improvement in
combined event rate and key processes in the 10 states
involved in this study, we cannot be sure that the improve-
ment was a result of the efforts of the QIOs. Many other
forces, including publications, may have influenced the
outcomes and process rates in the 10 states. It should be
emphasized that the quality improvement efforts by the
individual QIOs were voluntary, as was the participation by
individual providers within a state. The QIO in Georgia has
had a statewide effort to improve CEA results that dates
back 10 years, although we cannot be certain that the QIO
effort alone led to the benchmark outcomes achieved.16
The programs in the individual states were not standard-
ized, and we cannot determine which interventions were
associated with improvement. The size of the individual
state samples did not provide adequate power to determine
the relationship between intervention and improvement at
a state level. We can say that the adverse outcome outliers
improved in the remeasurement period.
We believe that quality improvement initiatives such as
the NNECDSG, DVANSQIP, and this project should be
encouraged in the future. Collecting relevant clinical data
does pose a resource burden on the providers, and this must
be recognized. It is important that standardized definitions
of indications, risk adjustment variables, and outcomes be
used for any comparisons. We suggest that the best quality
indicator for public reporting for CEA is the participation
in a standardized outcome reporting system that provides
peer comparison and local peer review, rather than public
reporting of the outcomes themselves. In addition, the
CEA process measures of preoperative antiplatelet admin-
istration and patching might be appropriate measures for
public reporting for any effort that has committed to public
reporting of CEA data.
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DISCUSSION
Dr A. R. Naylor (Leicester, England). This is an excellent
paper. I listened to your original presentation in 2000, when you
reported a 17% death/stroke rate after combined procedures. This,
in fact, that was a catalyst for our group to do what now has
become three very large systematic reviews on the natural history
and results of staged and synchronous surgery.
You’ve reduced the risk to 13%. That’s very commendable.
But there is no evidence anywhere in the world literature that the
risk for death and/or stroke with isolated CABG in patients with
severe, asymptomatic carotid disease is anywhere remotely near
that. Have you now stopped recommending combined procedures
in these states now?
Dr Timothy F. Kresowik. I would urge you to look at Dr
Kellie Brown’s paper, which was presented last year at this meeting
and published in the January 2003 issue of JVS.
One of the things we have to remember is that the combined
carotid/CABG patients are a very high-risk group of patients.
They’re not just an average coronary bypass patient. So I think it
would be unrealistic to compare them with typical coronary bypass
patients.
What Dr. Brown found in that study was that most of the
strokes have nothing to do with the ipsilateral carotid endarterec-
tomy. I think the high complication rate reflects the severity of the
disease of the patients. I would never say that the combined
procedure should never be done, but I must say that we do it
extremely rarely, and it would have to be for a symptomatic patient
in both distributions.
Dr John J. Ricotta (Stony Brook, NY). Tim, I’d like to make
a comment in reference to Dr Naylor’s comment, and then I’d like
to ask you a question.
Last month in Stroke we published a risk-adjusted analysis of
combined carotid CABG, and found no statistically significant
difference between what you would expect the stroke rate to be if
you did the CABG alone and what you saw when you did the
combined carotid CABG. I think this speaks to your point: that
these patients are very different and that risk adjustment is ex-
tremely important.
You have done a nice job of demonstrating the so-called
Hawthorne effect, that if you look at something you’re going to
improve the process. I wonder what you think we need to do to
take the next step. You are still reporting very high rates. It seems
to me that we’ve got to deal with the issues of accurate reporting
rather than self-reporting, and we have to deal with the issues of
risk adjustment. Whether a professional society like ours could play
a role, whether this is something the federal government needs to
do, or whether it’s something that needs to be done regionally
remains to be determined. However, I think if we’re going to make
more progress we have to move in that direction. I’d be interested
in your thoughts on that.
Dr Kresowik. I think the key thing that I believe is that we
need a standardized reporting mechanism, and it has to be very
simple. Data collection should be based on using indication and
outcome definitions that are standardized across the country. I also
believe that the reporting mechanisms have to be local and confi-
dential. I think it’s been shown that the improvement that hap-
pened in New York associated with public reporting was due to the
response of the surgeons and hospital staff, not to how the public
chose their surgeon or hospital. I would like to see outcome
reporting and quality improvement as a peer review process. I think
the Society for Vascular Surgery should play a role in defining those
indications strata and the outcome definitions.
Dr Peter K. Henke (Ann Arbor, Mich). Obviously, you’re
getting to the meat and potatoes that administrative database
reviews can only touch on. And the reason is because you’re able to
review those patients’ charts in depth. I wonder if you’d comment
on how the new HIPAA regulations are going to affect the ability
to do that. If you look at the majority of abstracts in this meeting,
most are from retrospective reviews and from which we get very
good knowledge. I think HIPAA is going to be a big detriment to
research.
Dr Kresowik. I would agree. We’ve had the benefit as part of
the quality improvement or peer review system that is clearly
excluded from some HIPAA requirements in the regulations.
There are certainly HIPAA issues that affect a lot of the other
outcome and quality improvement research.
Dr James C. Stanley (Ann Arbor, Mich). This work raises
questions regarding the data base from a random sampling of
complete medical chart reviews versus that of an administrative
discharge data base. A short while ago we published the outcomes
of carotid endarterectomy reflected in an administrative database
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(National Inpatient Sample) of more than 35,000 procedures
performed over a 2-year period (J Am Coll Surg 2002;195:814-
20). The most surprising outcome was that mortality and postop-
erative stroke rates after elective endarterectomy for high-volume
surgeons (those performing more than 30 procedures a year) were
0.32% and 1.02%, respectively. Such outcomes were much lower
than most benchmark data reported from statewide surveys such as
presented today. Even among emergent endarterectomies being
performed by low-volume surgeons (less than 10 procedures a
year) mortality was only 1.68% and stroke rate was 2.50%. Perhaps
more important were the differences in surgeon volume-related
outcomes that were independent of hospital volume or specialty
practice.
Although the information was confidential in your own data-
base, was a surgeon-volume effect assessed? Our report was based
on such large numbers that some of the vagaries of an administra-
tive data base may have been cancelled out. In this day and age
when initiatives like the Leapfrog project have placed such a great
emphasis on hospital volume, it would seem important to segre-
gate out such a simple factor as surgeon volume.
Dr Kresowik. It’s a very important question, and a question
I’d love to be able to answer. It’s problematic for us in terms of
individual surgeon identifiers in the hospital record. We have had
problems with getting CMS to allow us to look at some of these
questions, such as the importance of volume and/or specialty on
outcomes.
An important issue is that most of the studies on the volume/
outcome relationship for CEA using administrative data do not
correct for indication for the procedure. Many high-volume cen-
ters and surgeons have a high volume of asymptomatic patients,
who have a much lower risk for an adverse outcome.
The threshold for high volume changes from study to study.
Many times in the published reports the effects of volume on
outcome for CEA is quite weak. What I worry about is the perverse
incentive associated with the message that high quality is always
associated with the more you do. This message might create an
incentive to operate on the wrong patients. The asymptomatic
patient at high risk for complications because of medical comor-
bidities or with a low expected long-term survival should usually be
treated non-operatively. I worry that the focus on volume alone
will encourage surgeons to operate on more of these patients to
increase volume. We have the ability with this data base, if we can
get permission to do the linkages to the Part B claims system, to
maybe address your question in a much more evidence-based
manner.
Dr Richard P. Cambria (Boston, Mass). Quick question.
You have a large data set. You mentioned the process of preoper-
ative antiplatelet therapy. Have you looked at the data in terms of
the effect of preoperative antiplatelet therapy?
Dr Kresowik. In terms of the risk reduction?
Dr Cambria. In terms of the morbidity of surgery.
Dr Kresowik. There was no association with return to the OR
for bleeding with preoperative antiplatelet therapy, if that’s the
question.
Dr Cambria. The effect of preoperative antiplatelet therapy
on complications, not bleeding complications, stroke, and death.
Dr Kresowik. There is a statistically significant risk reduction
associated with preoperative antiplatelet therapy. The odds ratio
was 0.73, and it’s highly statistically significant.
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